Patient recruitment for the pivotal Diamyd® Phase 3 trial is progressing according to plan

Diamyd Medical today announced that patient recruitment for the single pivotal precision medicine Phase 3 trial DIAGNODE-3 is progressing according to plan. Patient recruitment is ongoing in eight European countries and is being prepared to start in the US this summer. The trial is expected to be fully enrolled during the summer of 2024.“We are very pleased to see that we are on target regarding our recruitment goals in this first of its kind precision medicine Phase 3 trial in type 1 diabetes”, says Ulf Hannelius, CEO of Diamyd Medical. “Patient recruitment is a crucial success factor for